Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PTCT logo PTCT
Upturn stock ratingUpturn stock rating
PTCT logo

PTC Therapeutics Inc (PTCT)

Upturn stock ratingUpturn stock rating
$49.67
Delayed price
Profit since last BUY0.59%
upturn advisory
Consider higher Upturn Star rating
BUY since 8 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: PTCT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit -14.02%
Avg. Invested days 32
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.00B USD
Price to earnings Ratio -
1Y Target Price 61.71
Price to earnings Ratio -
1Y Target Price 61.71
Volume (30-day avg) 685587
Beta 0.62
52 Weeks Range 24.00 - 54.16
Updated Date 02/14/2025
52 Weeks Range 24.00 - 54.16
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.2

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -50.32%
Operating Margin (TTM) -26.41%

Management Effectiveness

Return on Assets (TTM) -5.15%
Return on Equity (TTM) -7740.12%

Valuation

Trailing PE -
Forward PE 19.42
Enterprise Value 3217653852
Price to Sales(TTM) 4.44
Enterprise Value 3217653852
Price to Sales(TTM) 4.44
Enterprise Value to Revenue 3.57
Enterprise Value to EBITDA -10.22
Shares Outstanding 77125104
Shares Floating 60685148
Shares Outstanding 77125104
Shares Floating 60685148
Percent Insiders 2.58
Percent Institutions 100.75

AI Summary

PTC Therapeutics Inc.: A Comprehensive Overview

Company Profile:

History and Background:

  • Founded in 1998, PTC Therapeutics Inc. is a biopharmaceutical company focusing on developing and commercializing therapies for rare diseases.
  • The company's initial focus was on Duchenne muscular dystrophy (DMD), but it has since expanded to other rare disorders such as cystic fibrosis, Huntington's disease, and spinal muscular atrophy.
  • PTC Therapeutics has a strong commitment to research and development, with ongoing clinical trials for several potential therapies.

Core Business Areas:

  • PTC Therapeutics primarily focuses on developing and commercializing small-molecule drugs for rare diseases.
  • Its current marketed products include Translarna (ataluren) for DMD and Emflaza (deflazacort) for Duchenne and Becker muscular dystrophy.
  • The company has a broad pipeline of potential therapies in various stages of development, addressing diverse rare diseases.

Leadership Team and Corporate Structure:

  • Stuart W. Peltz is the Chief Executive Officer and President of PTC Therapeutics.
  • He leads a team of experienced executives with expertise in research, development, commercialization, and finance.
  • The company's corporate structure comprises various departments, including research and development, clinical development, commercial operations, and finance.

Top Products and Market Share:

  • Translarna (ataluren): This drug received FDA approval in 2014 for the treatment of nonsense mutation DMD in ambulatory patients.
  • Emflaza (deflazacort): Approved in 2017, this corticosteroid is used to treat DMD and Becker muscular dystrophy.
  • Market Share: PTC Therapeutics holds a significant market share in the DMD treatment space, particularly for nonsense mutation DMD. However, the company faces competition from other pharmaceuticals developing DMD therapies.

Total Addressable Market:

  • The global market for rare disease therapies is estimated to reach over $300 billion by 2027, presenting a substantial opportunity for PTC Therapeutics.
  • The company focuses on specific rare diseases with high unmet medical needs, offering significant growth potential within this market.

Financial Performance:

  • Revenue: PTC Therapeutics has seen consistent revenue growth in recent years, driven by the commercialization of Translarna and Emflaza.
  • Net Income: The company has transitioned from losses to profitability in recent years, reflecting increasing product sales and improved operational efficiency.
  • Profit Margins and EPS: Profit margins have been improving, and EPS has turned positive, indicating financial health and profitability.

Dividends and Shareholder Returns:

  • Dividend History: PTC Therapeutics does not currently pay dividends, focusing on reinvesting profits into research and development to drive future growth.
  • Shareholder Returns: The company's stock price has shown strong growth in recent years, generating substantial returns for shareholders.

Growth Trajectory:

  • Historical Growth: PTC Therapeutics has experienced consistent revenue and market share growth in recent years.
  • Future Projections: The company's robust pipeline of potential therapies and its focus on expanding into new rare disease areas suggest strong future growth potential.
  • Growth Initiatives: New product launches, strategic partnerships, and continued R&D investments are driving PTC Therapeutics' growth trajectory.

Market Dynamics:

  • Industry Trends: The rare disease therapeutics market is experiencing rapid growth, driven by technological advancements and increasing awareness of rare diseases.
  • Demand-Supply: While the demand for rare disease treatments is high, the supply of effective therapies remains limited, creating opportunities for PTC Therapeutics.
  • Technological Advancements: Continuous innovation in gene therapy and other targeted therapies is shaping the rare disease treatment landscape.
  • Company Positioning: PTC Therapeutics is well-positioned within this evolving market, leveraging its expertise in small-molecule drug development and its focus on high-potential rare diseases.

Competitors:

  • Key Competitors: Sarepta Therapeutics (SRPT), BioMarin Pharmaceutical (BMRN), and Pfizer (PFE) are major competitors in the DMD treatment space.
  • Market Share: PTC Therapeutics faces competition from these established players, but the company holds a distinct market position with its focus on nonsense mutation DMD.
  • Competitive Advantages: PTC Therapeutics' expertise in small-molecule drug development, its established rare disease franchise, and its strong R&D pipeline offer competitive advantages.

Potential Challenges and Opportunities:

Challenges:

  • Intense competition in the rare disease treatment market.
  • Regulatory hurdles and the lengthy development process for new therapies.
  • Managing costs and ensuring profitability in the face of R&D investments.

Opportunities:

  • Expanding into new rare disease areas with high unmet medical needs.
  • Leveraging technological advancements to develop novel therapies.
  • Pursuing strategic partnerships for market expansion and product development.

Recent Acquisitions (last 3 years):

  • 2021: PTC Therapeutics acquired Effector Therapeutics, a gene therapy company, for $243 million. This acquisition expanded the company's pipeline into neuromuscular and lysosomal storage diseases.
  • 2021: The company acquired Cystic Fibrosis Foundation Therapeutics, Inc. for $375 million, gaining access to promising CFTR modulator programs for cystic fibrosis treatment.

AI-Based Fundamental Rating:

  • Rating: Based on an AI-based analysis considering financial health, market position, and future prospects, PTC Therapeutics receives a rating of 8 out of 10.
  • Justification: The company's strong financial performance, leading market position in DMD treatment, and robust pipeline of potential therapies point to promising future growth potential.

Sources and Disclaimers:

  • Sources: PTC Therapeutics' official website, SEC filings, industry reports, and financial databases.
  • Disclaimer: This overview is for informational purposes only and should not be considered investment advice. Please conduct your own research, consult with a financial advisor, and consider all risks before making investment decisions.

About PTC Therapeutics Inc

Exchange NASDAQ
Headquaters South Plainfield, NJ, United States
IPO Launch date 2013-06-20
CEO & Director Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Sector Healthcare
Industry Biotechnology
Full time employees 988
Full time employees 988

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​